Uncover key drivers, emerging technologies, and competitive movements shaping the cytokine release syndrome treatment market from 2026–2035 with trusted insights from The Business Research Company
How is the Cytokine Release Syndrome Treatment Market size predicted to change over the forecast window of 2026–2035?
The cytokine release syndrome treatment market size has experienced rapid expansion in recent years. It is anticipated to expand from $1.42 billion in 2025 to $1.61 billion in 2026, reflecting a compound annual growth rate (CAGR) of 13.6%. The historical growth of this market can be attributed to the rise in advanced immunotherapy treatments, the broader adoption of car-t cell therapy, the availability of corticosteroids for immune modulation, heightened clinical awareness of cytokine storms, and improvements in critical care infrastructure.
The cytokine release syndrome treatment market size is projected to experience swift expansion over the coming years. This market is anticipated to reach a valuation of $2.66 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 13.3%. This expansion during the projection period can be attributed to several factors, including the increasing application of next-generation immunotherapies, a surge in investments directed towards cytokine modulation research, the broadening reach of oncology treatment centers, an intensified focus on individualized immune management, and the emergence of innovative anti-inflammatory biologics. Key trends anticipated during the forecast timeframe involve the expanded utilization of IL-6 and IL-1 targeted therapies, a growing uptake of monoclonal antibodies for crs management, the proliferation of hospital-based crs treatment protocols, an increasing incorporation of early diagnostic monitoring, and enhanced strategies for supportive care management.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20542&type=smp
Which Drivers Are Contributing To The Expansion Of The Cytokine Release Syndrome Treatment Market?
The increasing prevalence of cancer treatments is anticipated to drive the future growth of the cytokine release syndrome (CRS) treatment market. This rise in cancer therapies is propelled by the escalating global incidence of cancer and enhancements in diagnostic technologies, which facilitate earlier identification and a broader spectrum of treatment options. Moreover, better survival outcomes and expanded access to healthcare also contribute to the increasing need for these treatments. CRS treatment involves supportive measures, anti-cytokine medications, and continuous monitoring to manage symptoms and reduce the inflammatory reaction caused by cancer therapies. For example, in May 2024, data from the National Health Service (NHS), a healthcare provider in the UK, revealed that nearly 340,000 individuals received their initial cancer treatment over the past year, from April 2023 to March 2024. Furthermore, urgent suspected cancer referrals achieved a new record in March 2024, with 12,554 patients seen per working day, exceeding the prior record of 12,376 patients seen per working day in July 2023. Therefore, the growing number of cancer treatments is a key factor driving the cytokine release syndrome treatment market.
What Segment Classifications Make Up The Cytokine Release Syndrome Treatment Market?
The cytokine release syndrome treatment market covered in this report is segmented –
1) By Drug Type: Corticosteroids, Monoclonal Antibodies, Other Immunosuppressants
2) By Administration: Intravenous, Subcutaneous, Oral
3) By Application: Oncological Treatments, Autoimmune Disorders, Other Applications
4) By End User: Hospitals, Specialty Clinics, Home Care Settings
Subsegments:
1) Corticosteroids: Prednisone, Dexamethasone, Methylprednisolone
2) Monoclonal Antibodies: Tocilizumab (IL-6 Inhibitor), Siltuximab (IL-6 Inhibitor), Anakinra (IL-1 Receptor Antagonist)
3) Other Immunosuppressants: Janus Kinase (JAK) Inhibitors, Calcineurin Inhibitors, Tumor Necrosis Factor (TNF) Inhibitors
Which Trends Are Expected To Influence The Cytokine Release Syndrome Treatment Market In The Upcoming Years?
Leading companies in the cytokine release syndrome treatment market are advancing drug delivery methods like intravenous infusion to enhance treatment precision, reduce adverse effects, and improve patient outcomes. Intravenous infusion, when used for cytokine release syndrome, enables quick and accurate delivery of drugs into the bloodstream, ensuring swift therapeutic action. For example, in September 2023, Chugai Pharmaceutical Co. Ltd., a pharmaceutical company based in Japan, secured regulatory approval from the Ministry of Health, Labor, and Welfare, a Japanese government body, for Actemra (tocilizumab), a humanized anti-IL-6 receptor monoclonal antibody. This approval is for the treatment of cytokine release syndrome (CRS) induced by various cancer therapies. Actemra Intravenous Infusion, available in 80 mg, 200 mg, and 400 mg doses, represents an additional indication for managing cytokine release syndrome (CRS) caused by cancer therapy. With this new indication, Actemra can now be utilized as an anti-cytokine therapy for CRS resulting from cancer treatments beyond just tumor-specific T-cell infusion therapy.
Which Major Industry Participants Are Leading The Cytokine Release Syndrome Treatment Market Growth?
Major companies operating in the cytokine release syndrome treatment market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Thermo Fisher Scientific Inc., Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Regeneron Pharmaceuticals Inc., Chugai Pharmaceutical Co. Ltd., Incyte Corporation, Swedish Orphan Biovitrum AB (publ), Bio-Techne Corporation, GenScript Biotech Corporation, Abcam plc, Applied Biological Materials Inc., Poolbeg Pharma, arigo Biolaboratories Corp., CytoAgents Inc, bluebird bio Inc.
Access The Complete Report For Deeper Market Insights:
Which Region Is Expected To Experience The Fastest Growth In The Cytokine Release Syndrome Treatment Market?
North America was the largest region in the cytokine release syndrome treatment market in 2025. The regions covered in the cytokine release syndrome treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Cytokine Release Syndrome Treatment Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=20542&type=smp
Browse Through More Reports Similar to the Global Cytokine Release Syndrome Treatment Market 2026, By The Business Research Company
Drugs For Immunotherapy Market Report 2026
https://www.thebusinessresearchcompany.com/report/drugs-for-immunotherapy-global-market-report
Cellulars Immunotherapy Market Report 2026
https://www.thebusinessresearchcompany.com/report/cellulars-immunotherapy-global-market-report
Cancer Immunotherapy Market Report 2026
https://www.thebusinessresearchcompany.com/report/cancer-immunotherapy-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model